{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:00Z","timestamp":1791176880071,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["CRN-83320"],"award-info":[{"award-number":["CRN-83320"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Qu\u00e9bec Ministry of Health"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.vaccine.2013.06.064","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T15:01:48Z","timestamp":1372863708000},"page":"3863-3871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study"],"prefix":"10.1016","volume":"31","author":[{"given":"Marc","family":"Brisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Laprise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich V.","family":"Kliewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley L.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.06.064_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/000348949510401002","article-title":"Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis","volume":"104","author":"Pou","year":"1995","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens. Part B. Biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10552-008-9276-9","article-title":"Systematic review of human papillomavirus prevalence in invasive penile cancer","volume":"20","author":"Backes","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0030","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0045","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0055","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12\u201324 in a Phase III randomized study of healthy women aged 18\u201345 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0070","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"issue":"Suppl. 10","key":"10.1016\/j.vaccine.2013.06.064_bib0080","doi-asserted-by":"crossref","first-page":"K76","DOI":"10.1016\/j.vaccine.2008.06.009","article-title":"Modeling cervical cancer prevention in developed countries","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0085","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2458-11-203","article-title":"Cost-effectiveness of different human papillomavirus vaccines in Singapore","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurpub\/ckp141","article-title":"A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme","volume":"20","author":"Dee","year":"2010","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0100","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0105","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/1471-2458-12-872","article-title":"Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6\/11\/16\/18 vaccine in Canada","volume":"12","author":"Kohli","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2334-13-75","article-title":"Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"13","author":"Westra","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0115","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0120","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0125","doi-asserted-by":"crossref","unstructured":"Brisson M, Van de Velde N, Drolet M, Boily MC, Franco EL, Mayrand MH, et al. HPV-advise: technical appendix to J Natl Cancer Inst 2012; http:\/\/dx.doi.org\/10.1093\/jnci\/djs395. http:\/\/www.marc-brisson.net\/HPVadviseCEA.pdf.","DOI":"10.1093\/jnci\/djs395"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0130","series-title":"Report submitted to the Institut National de Sant\u00e9 Publique du Qu\u00e9bec (INSPQ)","article-title":"Efficacit\u00e9 populationnelle et co\u00fbt-efficacit\u00e9 des programmes de vaccination contre les VPH au Qu\u00e9bec","author":"Laprise","year":"2012"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0135","series-title":"Cost-effectiveness in health and medicine","author":"Shepard","year":"1999"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0140","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0272989X12454578","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5","volume":"32","author":"Pitman","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0145","series-title":"Investing in health for economic development. Report of the commission on macroeconomics and health","author":"WHO","year":"2001"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0150","series-title":"WHO-CHOICE: World Health Organization statistical information system: choosing interventions that are cost effective","author":"WHO","year":"2006"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0155","first-page":"1","article-title":"Vigie \u2013 Interventions: Couverture vaccinale en milieu scolaire","volume":"5","author":"Minist\u00e8re de la Sant\u00e9 et des Services Sociaux du Qu\u00e9bec (MSSS).","year":"2010","journal-title":"Flash Vigie"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0160","series-title":"Statistics Canada Canadian Community Health Survey (CCHS \u2013 Cycle 3.1)","year":"2005"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pon.2003","article-title":"The psychosocial impact of an abnormal cervical smear result","volume":"21","author":"Drolet","year":"2012","journal-title":"Psychooncology"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0170","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/OLQ.0b013e3182215512","article-title":"The impact of anogenital warts on health-related quality of life: a 6-month prospective study","volume":"38","author":"Drolet","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0175","series-title":"Epidemiology of cervical abnormalities and utilization of related health care resources","first-page":"49","author":"Demers","year":"2009"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0180","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/ijc.23459","article-title":"Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia","volume":"122","author":"Ades","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0185","first-page":"485","article-title":"The natural history of type-specific human papillomavirus infections in female university students","volume":"12","author":"Richardson","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.21897","article-title":"Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)","volume":"119","author":"Mayrand","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0195","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jmv.22081","article-title":"Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada","volume":"83","author":"Coutlee","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0200","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1525-1438.2001.011001024.x","article-title":"Cervical cancer in Canada: changing patterns in incidence and mortality","volume":"11","author":"Liu","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0210","unstructured":"Public Health Agency of Canada. Cancer surveillance on-line. Available at http:\/\/dsol-smed.phac-aspc.gc.ca\/dsol-smed\/cancer\/index-eng.php [accessed January 2011]."},{"key":"10.1016\/j.vaccine.2013.06.064_bib0215","series-title":"Cervical cancer screening program. 2009 annual report","author":"Cancer Agency","year":"2009"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/OLQ.0b013e318198de8c","article-title":"Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada","volume":"36","author":"Kliewer","year":"2009","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0225","series-title":"Abstract presented at the 27th international papillomavirus conference and clinical workshop","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 vaccine in women aged 15\u201325 years: follow-up to 9.4 years","author":"Naud","year":"2011"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0230","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0235","series-title":"Vaccines for the 21st century: a tool for decision making","author":"Institute of Medicine of the National Academies","year":"1999"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0240","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ijom.2006.07.017","article-title":"Patients\u2019 perceived health status following primary surgery for oral and oropharyngeal cancer","volume":"35","author":"Rogers","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","article-title":"A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females","volume":"9","author":"Anonychuk","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF03404377","article-title":"Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada","volume":"101","author":"Vijayaraghavan","year":"2010","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1741-7015-7-69","article-title":"Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis","volume":"7","author":"Kulasingam","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/sti.2008.030999","article-title":"Epidemiology and costs associated with genital warts in Canada","volume":"85","author":"Marra","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0265","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.LGT.0000171665.63976.B2","article-title":"Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada","volume":"9","author":"Benedet","year":"2005","journal-title":"J Low Genital Tract Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0270","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0275","doi-asserted-by":"crossref","first-page":"500 e1","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0280","series-title":"Surveillance epidemiology and end results national institutes of health","author":"NCI","year":"2006"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0285","first-page":"250","article-title":"Discounting in health care decision-making: time for a change","volume":"14","author":"Sheldon","year":"1992","journal-title":"J Public Health Med"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0290","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1473-3099(08)70258-5","article-title":"Funding of drugs: do vaccines warrant a different approach","volume":"8","author":"Beutels","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0295","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jval.2012.01.005","article-title":"On discounting of health gains from human papillomavirus vaccination: effects of different approaches","volume":"15","author":"Westra","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0300","series-title":"Recommendations on a human papillomavirus immunization program. Canadian Immunization Committee","author":"Public Health Agency of Canada","year":"2007"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0310","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0315","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0320","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2105\/AJPH.2011.300465","article-title":"Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007\u20132010","volume":"102","author":"Bauer","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0325","series-title":"Direction des risques biologiques et de la sant\u00e9 au travail","article-title":"La Vaccination contre les VPH au Qu\u00e9bec: Mise \u00e0 jour des connaissances et propositions du comit\u00e9 d\u2018experts","author":"Comit\u00e9 sur l\u2018immunisation du Qu\u00e9bec (CIQ)","year":"2012"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0330","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.064_bib0335","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/1471-2458-12-872","article-title":"Reviewer's report on Kohli, M. et al. \u201cModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and a HPV-6\/11\/16\/18 vaccine in Canada\u201d","volume":"12","author":"Jit","year":"2012","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.064_bib0340","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/1471-2458-12-872","article-title":"Reviewer's report on Kohli, M. et al. \u201cModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and a HPV-6\/11\/16\/18 vaccine in Canada\u201d","volume":"12","author":"Baussano","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0194599812437332","article-title":"Head and neck cancer in Canada: trends 1992 to 2007","volume":"147","author":"Johnson-Obaseki","year":"2012","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0350","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","article-title":"Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States","volume":"26","author":"Chaturvedi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0355","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/cncr.20998","article-title":"Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20\u201344 years","volume":"103","author":"Shiboski","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0360","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ijc.24339","article-title":"Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma","volume":"125","author":"Nasman","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0365","series-title":"Direction des risques biologiques et de la sant\u00e9 au travail","article-title":"La Vaccination contre les VPH au Qu\u00e9bec: Mise \u00e0 jour des connaissances et propositions du comit\u00e9 d\u2018experts","author":"Comit\u00e9 sur l\u2018immunisation du Qu\u00e9bec (CIQ)","year":"2012"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0370","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/jnci\/djs371","article-title":"Impact of the HIV epidemic on the incidence rates of anal cancer in the United States","volume":"104","author":"Shiels","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0375","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0380","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0385","series-title":"Abstract presented at the 26th international papillomavirus conference","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results","author":"Romanowski","year":"2010"},{"issue":"Suppl. 10","key":"10.1016\/j.vaccine.2013.06.064_bib0395","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0400","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0405","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1086\/590560","article-title":"Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV)","volume":"47","author":"Aubin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0410","series-title":"Abstract presented at the 24th international papillomavirus conference and clinical workshop","article-title":"The cost of treating anogenital warts in Manitoba, Canada","author":"Butler","year":"2007"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0415","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2011.10.067","article-title":"Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada","volume":"30","author":"Tully","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.064_bib0420","series-title":"SEER cancer statistics review, 1975\u20132007","author":"Altekruse","year":"2010"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T13:09:44Z","timestamp":1596028184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13008566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":83,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0264410X13008566"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}